{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:15Z","timestamp":1790701515286,"version":"4.1.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Translational Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.retram.2026.103603","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:36:46Z","timestamp":1784993806000},"page":"103603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging chimeric antigen receptor\u2013T cell therapy for the treatment of multiple sclerosis: Bridging oncology and neurology"],"prefix":"10.1016","volume":"74","author":[{"given":"Matlyuba","family":"Sanoyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza","family":"Nasirdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munisakhon","family":"Gulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza","family":"Ortikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Yumashev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ro'zibek","family":"Tolmasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgunbay","family":"Kholdarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanna R.","family":"Gardanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.retram.2026.103603_bib0001","article-title":"Emerging epidemiological trends of multiple sclerosis among adults aged 20\u201354 years, 1990\u20132021, with projections to 2035: a systematic analysis for the global burden of disease study 2021","volume":"16","author":"l\u2013y","year":"2025","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0002","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey","year":"2023","journal-title":"WIREs Mech Dis"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/neuroglia6010006","article-title":"Clinical management in multiple sclerosis","volume":"6","author":"Arredondo\u2013Robles","year":"2025","journal-title":"Neuroglia"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah\u2013Benyaich","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.retram.2026.103603_bib0006","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuroscience.2024.04.004","article-title":"Immune system dysregulation in the progression of multiple sclerosis: molecular insights and therapeutic implications","volume":"548","author":"Khan","year":"2024","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0007","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s43440-024-00642-0","article-title":"Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects","volume":"76","author":"Olejnik","year":"2024","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0008","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s13311-022-01246-3","article-title":"What have failed, interrupted, and withdrawn antibody therapies in multiple sclerosis taught us?","volume":"19","author":"Kr\u00e4mer","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.retram.2026.103603_bib0009","doi-asserted-by":"crossref","first-page":"1126421","DOI":"10.3389\/fimmu.2023.1126421","article-title":"Cell depletion therapies in autoimmune diseases: monoclonal antibodies or chimeric antigen receptor\u2013based therapy?","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1604174","article-title":"CAR T\u2013cells meet autoimmune neurological diseases: a new dawn for therapy","volume":"16","author":"Chinas","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.retram.2026.103603_bib0011","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/cells14100753","article-title":"Chimeric autoantibody receptor\u2013 and\/or peptide\u2013MHC\u2013based CAR therapies for targeted elimination of antigen\u2013specific B or T cells in hypersensitivity disorders such as allergies and autoimmune diseases","volume":"14","author":"Proti\u0107\u2013Rosi\u0107","year":"2025","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG\u2013specific CAR tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0013","article-title":"Dendritic cells as a nexus for the development of multiple sclerosis and models of disease","volume":"7","author":"Alakhras","year":"2023","journal-title":"Adv Biol (Weinh)"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0014","article-title":"Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale","volume":"2014","author":"Wade","year":"2014","journal-title":"Mult Scler Int"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T cell responses in the central nervous system","volume":"9","author":"Goverman","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0016","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029025","article-title":"Effector T cells in multiple sclerosis","volume":"8","author":"Kaskow","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"76","key":"10.1016\/j.retram.2026.103603_bib0017","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen\u2013specific depletion of CD4+ T cells by CAR T cells reveals distinct roles of higher\u2013 and lower\u2013affinity TCRs during autoimmunity","volume":"7","author":"Yi","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0018","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0065-2776(08)00404-5","article-title":"B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases","volume":"98","author":"McLaughlin","year":"2008","journal-title":"Adv Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0019","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/imm.13198","article-title":"The role of B cells in the immunopathogenesis of multiple sclerosis","volume":"160","author":"Gharibi","year":"2020","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0020","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4049\/jimmunol.1700920","article-title":"Betaine ameliorates experimental autoimmune encephalomyelitis by inhibiting dendritic cell\u2013derived IL\u20136 production and Th17 differentiation","volume":"200","author":"Yang","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0021","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fimmu.2018.01112","article-title":"Insight into non\u2013pathogenic Th17 cells in autoimmune diseases","volume":"9","author":"Wu","year":"2018","journal-title":"Front Immunol"},{"issue":"310","key":"10.1016\/j.retram.2026.103603_bib0022","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM\u2013CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"issue":"1\u20132","key":"10.1016\/j.retram.2026.103603_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jneuroim.2011.08.019","article-title":"Reduction in IL\u201310 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naive\/memory breg ratio during a relapse but not in remission","volume":"239","author":"Knippenberg","year":"2011","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1270","article-title":"TGF\u2013\u03b2\u2013secreting regulatory B cells: unsung players in immune regulation","volume":"10","author":"Huai","year":"2021","journal-title":"Clin Transl Immunology"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1474-4422(24)00140-6","article-title":"Mougiakakos D. B cell\u2013targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases","volume":"23","author":"Haghikia","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.retram.2026.103603_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1562662","article-title":"Chimeric autoantibody receptor T cells specifically eliminate Graves\u2019 Disease autoreactive B cells","volume":"16","author":"Cheever","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR\u2013T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"eBioMedicine"},{"key":"10.1016\/j.retram.2026.103603_bib0028","article-title":"CAR T\u2013cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR\u2013T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96976","article-title":"Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation","volume":"3","author":"Guedan","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0031","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor\u2013zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0032","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T\u2013lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0033","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4\u20131BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0034","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pul\u00e8","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2026.103603_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1034707","article-title":"Next generations of CAR\u2013T cells \u2013 new therapeutic opportunities in hematology?","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.retram.2026.103603_bib0036","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/hum.2013.209","article-title":"A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer","volume":"25","author":"Abate\u2013Daga","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.1016\/j.retram.2026.103603_bib0037","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR\u2013T cells with cytokines and more: innovations in the fourth\u2013generation CAR\u2013T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.retram.2026.103603_bib0038","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0039","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR\u2013T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR\u2013T: what is next?","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0041","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0042","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40291-024-00730-0","article-title":"The future of CAR T therapeutics to treat autoimmune disorders","volume":"28","author":"Pecher","year":"2024","journal-title":"Mol Diagn Ther"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0043","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T\u2013cell therapy in myasthenia gravis (MG\u2013001): a prospective, multicentre, open\u2013label, non\u2013randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0044","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis \u2014 From targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.retram.2026.103603_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106400","article-title":"Early extended interval dosing of rituximab in multiple sclerosis: a comparative cohort study on efficacy and safety","volume":"97","author":"Fossum","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0046","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.retram.2026.103603_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1352458517740641","article-title":"Safety and tolerability of inebilizumab (MEDI\u2013551), an anti\u2013CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo\u2013controlled, escalating intravenous and subcutaneous dose study","volume":"25","author":"Agius","year":"2019","journal-title":"Mult Scler"},{"key":"10.1016\/j.retram.2026.103603_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233041","article-title":"A review of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis","volume":"17","author":"Airas","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.retram.2026.103603_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123938","article-title":"Substituted 2\u2013pyrrolinone compounds as inhibitors of B\u2013cell activating factor (BAFF) for autoimmune diseases treatment","volume":"380","author":"Olla","year":"2025","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.retram.2026.103603_bib0050","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3325\/cmj.2019.60.87","article-title":"Therapies for multiple sclerosis targeting B cells","volume":"60","author":"Milo","year":"2019","journal-title":"Croat Med J"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0051","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.medj.2024.04.005","article-title":"CD19 CAR T cells for multiple sclerosis: forging further into the new frontier","volume":"5","author":"Rankin","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.retram.2026.103603_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2025.103164","article-title":"CAR T\u2013cell therapy in autoimmune diseases: opportunities and challenges, with implications for RA","volume":"98","author":"Hojati Shargh","year":"2026","journal-title":"Tissue Cell"},{"issue":"9","key":"10.1016\/j.retram.2026.103603_bib0053","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR\u2013T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.retram.2026.103603_bib0054","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.trecan.2025.08.014","article-title":"CAR T cell persistence in cancer","volume":"11","author":"Mueller","year":"2025","journal-title":"Trends Cancer"},{"issue":"23","key":"10.1016\/j.retram.2026.103603_bib0055","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti\u2013BCMA CAR\u2013T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.retram.2026.103603_bib0056","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B\u2013cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real\u2013world chimeric antigen receptor consortium report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0057","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR\u2013T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"issue":"19","key":"10.1016\/j.retram.2026.103603_bib0058","doi-asserted-by":"crossref","first-page":"9669","DOI":"10.3390\/ijms26199669","article-title":"Limitations of CAR\u2013T\u2013cell therapy in hematologic malignancies: focusing on antigen escape and T\u2013cell dysfunction","volume":"26","author":"Lin","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.retram.2026.103603_bib0059","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti\u2013BCMA CAR\u2013T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.retram.2026.103603_bib0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR\u2013T cell therapy: mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0061","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long\u2013lived plasma cells and humoral immunity in individuals responding to CD19\u2013directed CAR T\u2013cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0062","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-025-00736-8","article-title":"Advances in engineered T cell immunotherapy for autoimmune and other non\u2013oncological diseases","volume":"13","author":"Huang","year":"2025","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0063","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR\u2013T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow TransPlant"},{"issue":"95","key":"10.1016\/j.retram.2026.103603_bib0064","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single\u2013cell analysis of anti\u2013BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103603_bib0065","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1182\/blood-2024-199874","article-title":"Development of allogeneic dual\u2013targeting CD19\/BCMA CAR\u2013T cell therapeutics using ALL\u2013in\u2013one site\u2013specific integration technology for autoimmune diseases","volume":"144","author":"Li","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0066","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual\u2013target chimeric antigen receptor T\u2013cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J Immunol Res"},{"key":"10.1016\/j.retram.2026.103603_bib0067","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ard.2025.05.458","article-title":"POS0061\u2005Bcma\u2013Cd19 dual\u2013targeting car\u2013T cell for the treatment of refractory thrombocytopenia associated with autoimmune diseases","volume":"84","author":"Yang","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.retram.2026.103603_bib0068","article-title":"Engineered regulatory T cells expressing myelin\u2013specific chimeric antigen receptors suppress EAE progression","volume":"358","author":"De","year":"2020","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0069","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood-2004-09-3579","article-title":"Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes","volume":"105","author":"Mekala","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103603_bib0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3\u2013engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.retram.2026.103603_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR\u2013T cells and CAR\u2013tregs targeting conventional type\u20131 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0072","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41541-024-00869-1","article-title":"High production of IL\u201312 by human dendritic cells stimulated with combinations of pattern\u2013recognition receptor agonists","volume":"9","author":"Gilmour","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0073","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88448-5","article-title":"Multiple sclerosis patients have reduced resting and increased activated CD4+CD25+FOXP3+T regulatory cells","volume":"11","author":"Verma","year":"2021","journal-title":"Sci Rep"},{"issue":"6295","key":"10.1016\/j.retram.2026.103603_bib0074","first-page":"179","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science (1979)"},{"issue":"9","key":"10.1016\/j.retram.2026.103603_bib0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen\u2013specific B cells in muscle\u2013specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"issue":"107","key":"10.1016\/j.retram.2026.103603_bib0076","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adm8186","article-title":"Chimeric autoantibody receptor T cells clonally eliminate B cells producing autoantibodies against IFN\u2013\u03b3","volume":"10","author":"Peng","year":"2025","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0077","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.kint.2024.01.021","article-title":"An antigen\u2013specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti\u2013PLA2R1 and anti\u2013THSD7A antibody\u2013secreting cells","volume":"105","author":"Seifert","year":"2024","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.retram.2026.103603_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19763","article-title":"Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: an in\u2013vitro study","volume":"9","author":"Sahlolbei","year":"2023","journal-title":"Heliyon"},{"issue":"22","key":"10.1016\/j.retram.2026.103603_bib0079","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers16223776","article-title":"Unlocking intracellular oncology targets: the unique role of antibody\u2013based T\u2013cell receptor mimic (TCRm) therapeutics in T\u2013cell engagers (TCEs) and antibody\u2013drug conjugates (ADCs)","volume":"16","author":"Molldrem","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0080","first-page":"22","article-title":"T\u2013cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins","volume":"2","author":"Xu","year":"2019","journal-title":"Antib Ther"},{"issue":"21","key":"10.1016\/j.retram.2026.103603_bib0081","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1182\/blood-2014-01-549022","article-title":"A TCR\u2013mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR\u2013ABL+ leukemias","volume":"123","author":"Dubrovsky","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004035","article-title":"Development of a TCR\u2013like antibody and chimeric antigen receptor against NY\u2013ESO\u20131\/HLA\u2013A2 for cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J ImmunOther Cancer"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0083","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1172\/JCI92335","article-title":"A therapeutic T cell receptor mimic antibody targets tumor\u2013associated PRAME peptide\/HLA\u2013I antigens","volume":"127","author":"Chang","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0084","article-title":"Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma","volume":"12","author":"Liu","year":"2022","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.retram.2026.103603_bib0085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010248","article-title":"MAGE\u2013A4 pMHC\u2013targeted CAR\u2013T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity","volume":"12","author":"Liu","year":"2024","journal-title":"J ImmunOther Cancer"},{"key":"10.1016\/j.retram.2026.103603_bib0086","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1582944","article-title":"Comparison of efficacy and adverse effects of CD19\/20 CART versus CD19 single\u2013target CART in R\/R DLBCL: a single\u2013center retrospective study","volume":"16","author":"Xue","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115888","article-title":"The paths and challenges of \"off\u2013the\u2013shelf\" CAR\u2013T cell therapy: an overview of clinical trials","volume":"169","author":"Moradi","year":"2023","journal-title":"Biomed PharmacOther"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0088","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41232-025-00398-x","article-title":"Harnessing the potential of gene editing technology for CAR\u2013T cell therapy of solid tumors","volume":"45","author":"Khodabandehloo","year":"2025","journal-title":"Inflamm Regen"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0089","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","article-title":"Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future","volume":"9","author":"Mougiakakos","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"10.1016\/j.retram.2026.103603_bib0090","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19\u2013targeted CAR\u2013T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.retram.2026.103603_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1388475","article-title":"Progress and pitfalls of gene editing technology in CAR\u2013T cell therapy: a state\u2013of\u2013the\u2013art review","volume":"14","author":"Moradi","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.retram.2026.103603_bib0092","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1491282","article-title":"Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)\u2013based immunotherapy: recent advances, challenges, and future prospects","volume":"12","author":"Alidadi","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"15_suppl","key":"10.1016\/j.retram.2026.103603_bib0093","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2021.39.15_suppl.2527","article-title":"Safety and PK\/PD of ALLO\u2013647, an anti\u2013CD52 antibody, with fludarabine (Flu)\/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR\u2013T cell therapy","volume":"39","author":"Tees","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103603_bib0094","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2024-210846","article-title":"Alloimmune defense receptor combined with genetic ablation of adhesion ligand CD58 is a comprehensive approach to promote functional persistence of allogeneic cell therapies without conditioning chemotherapy","volume":"144","author":"Williams","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR\u2013T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0096","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19\u2013targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103603_bib0097","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1182\/blood-2024-205103","article-title":"CD19\u2013Directed CAR T cell therapy in 4 patients with refractory multiple sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.retram.2026.103603_bib0098","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti\u2013CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.retram.2026.103603_bib0099","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T\u2013cell therapy in autoimmune disease \u2013 a case series with follow\u2013up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.retram.2026.103603_bib0100","first-page":"1573","article-title":"Tolerability of CAR T cell therapy in autoimmune disease [abstract]","volume":"75","author":"Taubmann","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.retram.2026.103603_bib0101","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/annrheumdis-2024-eular.3334","article-title":"POS0030\u2005Safety and preliminary efficacy of Cd19 car\u2013T cell treatment in rheumatic disease\u2013 data from the first part of the phase I\/ii castle basket study","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"16_suppl","key":"10.1016\/j.retram.2026.103603_bib0102","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2023.41.16_suppl.7528","volume":"41","author":"Frigault","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.retram.2026.103603_bib0103","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T\u2013cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.retram.2026.103603_bib0104","doi-asserted-by":"crossref","first-page":"3469.1","DOI":"10.1182\/blood-2024-204169","article-title":"A study of Kyv\u2013101, a CD19 CAR T cell therapy, in participants with treatment refractory progressive multiple sclerosis","volume":"144","author":"Seshadri","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.retram.2026.103603_bib0105","first-page":"2443","article-title":"How I treat unique and difficult\u2013to\u2013manage cases of CAR T\u2013cell therapy\u2013associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103603_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107958","article-title":"Critical care considerations of chimeric antigen receptor (CAR) T\u2013cell therapy","volume":"238","author":"Ponnapalli","year":"2025","journal-title":"Respir Med"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0107","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM\u2013CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR\u2013T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2016005","article-title":"IL\u20136\/IFN\u2013\u03b3 double knockdown CAR\u2013T cells reduce the release of multiple cytokines from PBMCs in vitro","volume":"18","author":"Zhang","year":"2022","journal-title":"Hum Vaccin ImmunOther"},{"issue":"23","key":"10.1016\/j.retram.2026.103603_bib0109","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T\u2013cell\u2013associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.retram.2026.103603_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1511931","article-title":"Novel gene manipulation approaches to unlock the existing bottlenecks of CAR\u2013NK cell therapy","volume":"12","author":"Dehghan","year":"2025","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"10.1016\/j.retram.2026.103603_bib0111","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ymthe.2025.12.022","article-title":"Redefining multiple sclerosis with CAR\u2013T cell therapy","volume":"34","author":"Li","year":"2026","journal-title":"Mol Ther"},{"key":"10.1016\/j.retram.2026.103603_bib0112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1142597","article-title":"The peculiar challenge of bringing CAR\u2013T cells into the brain: perspectives in the clinical application to the treatment of pediatric central nervous system tumors","volume":"14","author":"Del Baldo","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.retram.2026.103603_bib0113","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106812","article-title":"CAR T cells for multiple sclerosis: engineering T cells to disrupt chronic B cell\u2013driven neuroinflammation","volume":"104","author":"Ortu\u00f1o\u2013Sahag\u00fan","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"suppl 9","key":"10.1016\/j.retram.2026.103603_bib0114","article-title":"KITE-363: An autologous anti-CD19\/CD20 CAR-T product for the treatment of autoimmune rheumatic diseases [abstract]","volume":"77","author":"Kim","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ekir.2025.10.008","article-title":"Bicistronic\u2013CD19\/22 chimeric antigen receptor T\u2013cell therapy for childhood refractory lupus nephritis","volume":"11","author":"Mao","year":"2026","journal-title":"Kidney Int Rep\u00ae"},{"issue":"4","key":"10.1016\/j.retram.2026.103603_bib0116","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF\u2013R dual\u2013targeted CAR T cells for the treatment of mixed antigen\u2013negative variants of acute lymphoblastic leukemia","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.retram.2026.103603_bib0117","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/d41573-025-00184-x","article-title":"CAR\u2013T cells drive into progressive multiple sclerosis","volume":"24","author":"Villanueva","year":"2025","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","article-title":"BCMA\u2013CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow\u2013up of a phase 1 clinical trial","volume":"19","author":"Hong","year":"2026","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0119","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.retram.2026.103603_bib0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.07.030","article-title":"Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter?","volume":"25","author":"Pryce","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.retram.2026.103603_bib0121","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cyto.b.20603","article-title":"Flow cytometric characterization of cerebrospinal fluid cells","volume":"80B","author":"de Graaf","year":"2011","journal-title":"Cytom B: Clin Cytom"},{"key":"10.1016\/j.retram.2026.103603_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2024.1337339","article-title":"Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation","volume":"18","author":"Tieck","year":"2024","journal-title":"Front Cell Neurosci"},{"issue":"7","key":"10.1016\/j.retram.2026.103603_bib0123","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/eji.200737784","article-title":"Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin\u2013specific antibodies","volume":"38","author":"von B\u00fcdingen","year":"2008","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.retram.2026.103603_bib0124","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B\u2013cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol"},{"issue":"2","key":"10.1016\/j.retram.2026.103603_bib0125","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR\u2013T cell manufacturing: major process parameters and next\u2013generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"Suppl 1","key":"10.1016\/j.retram.2026.103603_bib0126","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T\u2013cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.retram.2026.103603_bib0127","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR\u2013T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/j.retram.2026.103603_bib0128","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100027","article-title":"In vivo generation of CAR T cells: biology, delivery platforms, clinical promise, and translational challenges","volume":"2","author":"Volta","year":"2026","journal-title":"Blood Immunol Cell Ther"},{"key":"10.1016\/j.retram.2026.103603_bib0129","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1007\/s12094-025-04185-5","article-title":"Emerging strategies to reduce the side effects of CAR\u2013T cell therapy: focusing on gene editing and nanotechnology","volume":"28","author":"Dong","year":"2026","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.retram.2026.103603_bib0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV\u2013mediated in vivo CAR gene therapy for targeting human T\u2013cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.retram.2026.103603_bib0131","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood-2025-252","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.retram.2026.103603_bib0132","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In Vivo CD19 CAR T\u2013cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.retram.2026.103603_bib0133","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41584-025-01313-x","article-title":"In vivo CAR\u2013T cell engineering in refractory SLE","volume":"21","author":"Papatriantafyllou","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.retram.2026.103603_bib0134","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1016\/j.apsb.2026.03.033","article-title":"In situ generation of EBNA1 CAR\u2013T cells eradicates antigen specific auto\u2013immune B cells for multiple sclerosis treatment","volume":"16","author":"Shi","year":"2026","journal-title":"Acta Pharm Sin B"}],"container-title":["Current Research in Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452318626000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:31:43Z","timestamp":1790699503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452318626000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2452318626000395"],"URL":"https:\/\/doi.org\/10.1016\/j.retram.2026.103603","relation":{},"ISSN":["2452-3186"],"issn-type":[{"value":"2452-3186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leveraging chimeric antigen receptor\u2013T cell therapy for the treatment of multiple sclerosis: Bridging oncology and neurology","name":"articletitle","label":"Article Title"},{"value":"Current Research in Translational Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.retram.2026.103603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103603"}}